QC
ARQT icon

Quadrature Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

Quadrature Capital’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$363K Sell
13,855
-9,302
-40% -$217K ﹤0.01% 1134
2026
Q1 		$546K Buy
+23,157
New +$591K 0.01% 764
2025
Q2 		– Sell
-11,026
Closed -$172K – 1038
2025
Q1 		$172K Buy
+11,026
New +$155K ﹤0.01% 876

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Quadrature Capital's ARQT Position: Q2 2026 in Review

Quadrature Capital reduced its Arcutis Biotherapeutics (ARQT) stake by 40% in Q2 2026, selling an estimated $217K and leaving 13,855 shares worth $363K. The position accounts for ﹤0.01% of the portfolio, ranked #1134.

Quadrature Capital first reported a position in ARQT in Q1 2025 and has held it in 3 quarters since. The position peaked at $546K in Q1 2026. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Quadrature Capital held 13,855 shares of Arcutis Biotherapeutics worth $363K as of Q2 2026.
  • Quadrature Capital sold 9,302 Arcutis Biotherapeutics shares in Q2 2026, an estimated $217K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1134 holding.
  • Quadrature Capital first reported a position in Arcutis Biotherapeutics in Q1 2025 and has held it in 3 quarters since.
  • Quadrature Capital's Arcutis Biotherapeutics position peaked at $546K in Q1 2026.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.